Pharmaceutical giant Celgene injects major funds into academic synthetic antibody research and development

By CCAB - September 15, 2015 4:28 pm (leave your thoughts)

Pharmaceutical giant Celgene injects major funds into academic synthetic antibody research and development

September 2015 – The pharmaceutical company Celgene has indicated its intense interest in the development of biologics, notably synthetic antibodies, in the form of a 3-year, US $25 million sponsorship of the Recombinant Antibody Network (RAN). The RAN, a consortium of US- and Canada-based academic labs dedicated to the development of synthetic antibodies with therapeutic applications, was founded by CCAB CEO Dr. Sidhu and Drs. Anthony Kossiakoff (UChicago) and Jim Wells (UCSF). The Celgene collaboration will focus on the development of therapeutic antibodies for cancer, inflammation, and immunological disorders.

“Through this partnership, we are taking a giant step forward in the ultimate goal of the RAN: the systematic targeting of the “extra-cellularome,” the cell-surface proteins that control cancer and other diseases”, says Dr. Sidhu. “In the future, we envision that we will be able to precisely target cancer cells at the molecular level, which will provide better therapies for patients”.


Leave a Reply